Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec reports successful third quarter

Biogen Idec reports successful third quarter

29th October 2010

Biogen Idec has published its financial report for the third quarter of 2010, noting its success in pursuing financial and clinical goals during the period.

Over the three months ending on September 30th 2010, the company generated revenues of $1.2 billion (755.5 million pounds), representing a year-over-year increase of five percent.

During the quarter, Biogen Idec saw improvements in sales of key drug products Avonex and Tysabri, while also making progress in its efforts to expand the labelling of the latter drug.

The firm was also able to sign agreements with Genentech and Knopp Neurosciences to amend or begin research collaborations towards several key therapy targets.

Biogen Idec chief executive officer Dr George Scangos said: "We also continued to demonstrate our leadership position in multiple sclerosis … while expanding our neurology foothold with the licensing agreement for KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis."

Dr Scangos has occupied the leadership role at Biogen Idec since July 2010, when he replaced the retired former chief executive officer James Mullen.ADNFCR-8000103-ID-800201872-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.